OKYO Pharma to Ring the Opening Bell at Nasdaq
MWN-AI** Summary
On December 19, 2025, OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical firm, proudly announced that its Executive Chairman and Founder, Gabriele Cerrone, will ring the Opening Bell at Nasdaq MarketSite in New York City. This event not only marks a significant milestone for the company but also celebrates the ongoing advancements in its innovative therapies, particularly its lead candidate, urcosimod, aimed at treating neuropathic corneal pain (NCP).
NCP, a debilitating ocular condition resulting from nerve damage and inflammation, currently lacks an FDA-approved treatment, highlighting the significance of OKYO's work. Urcosimod, a lipid-conjugated chemerin peptide agonist, targets the ChemR23 G-protein-coupled receptor found in immune cells and neurons, offering a new therapeutic approach. The recent positive Phase 2 trial results for urcosimod have demonstrated favorable outcomes in pain reduction and corneal nerve health, strengthening the case for its potential to transform patient care.
During the ceremony, Cerrone expressed pride in the company's achievements, emphasizing the team's dedication to enhancing patient outcomes through groundbreaking therapies. The event, set to be broadcasted live at 9:30 AM ET, symbolizes OKYO's commitment to addressing unmet medical needs in ocular health.
Looking ahead, OKYO Pharma plans to initiate a larger multicenter trial of urcosimod for NCP in Q1 2026, further solidifying its position as a leading innovator in the biopharmaceutical industry. With its shares listed on the NASDAQ Capital Market, OKYO continues to focus on advancing its pipeline for innovative treatments enhancing the quality of life for patients suffering from chronic ocular pain. For more information, visit www.okyopharma.com.
MWN-AI** Analysis
As OKYO Pharma Limited (NASDAQ: OKYO) prepares to ring the Opening Bell on December 19, 2025, this event holds significant implications for both the company's visibility and its market trajectory. With its innovative product urcosimod targeting neuropathic corneal pain (NCP), a condition currently lacking FDA-approved treatments, OKYO is positioned at the forefront of addressing an unmet medical need in the biopharmaceutical landscape.
The positive Phase 2 trial results for urcosimod are a critical milestone. Demonstrating statistically significant outcomes in pain reduction and corneal nerve improvement could bolster investor confidence and enhance the stock's appeal. As the company gears up for a larger, multicenter trial in 2026, the market sentiment is likely to lean towards optimism, especially amid a backdrop of rising interest in biotech investments.
From a market perspective, investors should closely monitor the upcoming data releases and trial outcomes. The ringing of the bell during this high-visibility event can generate media buzz, potentially enhancing retail and institutional investor interest. This is critical for a company like OKYO, which is still navigating the challenges typical of clinical-stage biotech firms.
Moreover, the company's leadership, particularly Gabriele Cerrone's commitment to improving patient outcomes, reinforces a narrative of dedication and innovation. This narrative can create a favorable cultural sentiment around the stock.
However, investors should remain cautious of the inherent risks in biotech investing, particularly clinical trial failures or delays, which can lead to volatility. It is prudent to maintain a diversified portfolio and consider potential entry points that reflect both the company's promising pipeline and the broader market conditions.
Overall, as OKYO rings in this significant milestone, the encouraging developments in their clinical trajectory combined with strategic investor communications promise to strengthen their market position in the coming months.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LONDON and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company which is developing urcosimod to treat neuropathic corneal pain (NCP), an ocular condition associated with chronic and often severe nerve-related pain but without an FDA-approved therapy, announced that Executive Chairman and Founder, Gabriele Cerrone and the OKYO management team will ring the Opening Bell at the Nasdaq MarketSite in Times Square, New York today.
The ceremony will be held from 9:15 AM to 9:45 AM ET, and celebrates OKYO's ongoing advancements in innovative treatments, including its lead candidate urcosimod, a lipid-conjugated chemerin peptide agonist targeting the ChemR23 G-protein-coupled receptor. The company's novel approach aims to address a significant unmet need in neuropathic corneal pain (NCP) where there are no FDA-approved therapies currently available.
"This is a proud moment for OKYO Pharma and a testament to the hard work and dedication of our exceptional team who are working to improve patient outcomes," said Gabriele Cerrone, Executive Chairman and Founder of OKYO Pharma. "Ringing the Nasdaq Opening Bell is a powerful celebration of our unwavering commitment to transforming patient outcomes through groundbreaking therapies for ocular pain. We are excited about the future as we advance our clinical programs and deliver on our mission to address unmet medical needs."
OKYO Pharma continues to progress its pipeline, with recent achievements including positive Phase 2 results for urcosimod in neuropathic corneal pain, demonstrating favourable corneal nerve outcomes and pain reduction.
The Opening Bell ceremony will be broadcast live at 9:30 a.m. ET and live streamed to Nasdaq's official channels.
To view the live broadcast, visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony
About Neuropathic Corneal Pain (NCP)
NCP is a condition that causes severe pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but is thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated, with limited success by various topical and systemic treatments in an off-label fashion. There is presently no FDA-approved drug to treat NCP.
About Urcosimod (formerly called OK-101)
Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a corneal neuropathic pain mouse model, respectively. Urcosimod showed clear statistical significance in multiple endpoints in an earlier 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease, and OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and is currently planning a second larger, multicenter trial of urcosimod in NCP patients that is planned to start in Q1 2026.
For further information, please visit www.okyopharma.com.
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | +44 (0)20 7495 2379 |
| Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ**
How might the advancements of OKYO Pharma Limited (OKYO) in treating neuropathic corneal pain impact investor sentiment in biotech sectors in New York and London by late 2025?
What are the expected challenges for OKYO Pharma Limited (OKYO) as it progresses its clinical trials in both New York and London markets?
With the positive Phase 2 results for urcosimod, how could OKYO Pharma Limited (OKYO) leverage its success to attract investments from institutional investors in both London and New York?
In the context of global biopharma investment trends, how does OKYO Pharma Limited (OKYO) plan to compete with other firms focusing on ocular therapies in major financial hubs like London and New York?
**MWN-AI FAQ is based on asking OpenAI questions about OKYO Pharma Limited (NASDAQ: OKYO).
NASDAQ: OKYO
OKYO Trading
2.15% G/L:
$1.66 Last:
147,738 Volume:
$1.65 Open:
